主页 > 医学动态 >
【medical-news】2008 ASCO报道之二：抗贫血药可诱发
Anemia drugs sold by Amgen and J&J have been under the safety spotlight for a while now, with some research suggesting the drugs may stimulate the growth of tumors in cancer patients. A study presented at this year’s American Society of Clinical Oncology conference points to a possible method for figuring out which patients are more (and less) likely to be harmed by the drugs.
Researchers at the University of Washington looked at the expression of the gene for the erythropoietin receptor (EpoR) — the same receptor targeted on blood cells by the anemia drugs, which include Amgen’s Aranesp and Johnson & Johnson’s Procrit.
In a group of patients with head and neck cancer, activity in tumor genes for EpoR was correlated with bad outcomes for paitents.
The study is small (it was based on tumor samples from a little over a hundred patients) and the findings are preliminary. For that matter, the safety of these drugs in cancer patients is still unclear; the most worrying results have come from studies in which patients received higher-than-recommended doses.
Still, the hypothesis suggested by the study fits with a theme that’s captured our attention here at the conference: using biomarkers to figure out which patients should and shouldn’t receive certain drugs. If more data emerge to suggest that anemia drugs are indeed risky for cancer patients, it might be in the interest of Amgen and J&J to identify those cancer patients at lower risk.
Amgen wasn’t involved in the study; in a statement, the company said there is “no definitive evidence of Epo-receptor (Epo-R) involvement in tumor progression,” adding that the company is studying the subject.
Tony Blau, the lead researcher, said he needs access to more tumor samples from patients in anemia drug trials. “The definitive answer to this question lies locked in the files of pathologists’ offices,” he said this morning.
An Amgen spokeswoman said the company has not systematically collected tumor samples in its previous trials, but will be doing so in the future.
http://blogs.wsj.com/health/2008/06/01/gene-may-point-to-risk-for-anemia-drugs/
screen.width-333)this.width=screen.width-333" width=200 height=47 title="Click to view full amgen_art_200_20071207123816.jpg (200 X 47)" border=0 align=absmiddle> 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 抗贫血药可能诱发更多的肿瘤
之前也有报道的
但是ASCO发现，这个易感性可能与基因有关 期望有进一步的确切，而且系统的研究结论得出。
当然，该研究由于非热点，经济效益可能欠佳。因此，我们是否不该抱太大的希望？
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-10-01 11:08
医学,生命科学网